JP2024525954A - 二置換１，２，４－トリアジン化合物の塩を含む可溶性薬学的組成物 - Google Patents

二置換１，２，４－トリアジン化合物の塩を含む可溶性薬学的組成物 Download PDF

Info

Publication number
JP2024525954A
JP2024525954A JP2024504002A JP2024504002A JP2024525954A JP 2024525954 A JP2024525954 A JP 2024525954A JP 2024504002 A JP2024504002 A JP 2024504002A JP 2024504002 A JP2024504002 A JP 2024504002A JP 2024525954 A JP2024525954 A JP 2024525954A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
salt
weight
compound
milligrams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525954A5 (https=
Inventor
マッキーン，ロバート
ヨシノリ オオハシ
文則 尾▲崎▼
ヒロキ オオシマ
ヒロオミ ナガタ
ティバート，ロック
バダス，エリザベス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mineralys Therapeutics Inc
Original Assignee
Mineralys Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mineralys Therapeutics Inc filed Critical Mineralys Therapeutics Inc
Publication of JP2024525954A publication Critical patent/JP2024525954A/ja
Publication of JP2024525954A5 publication Critical patent/JP2024525954A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024504002A 2021-07-20 2022-07-20 二置換１，２，４－トリアジン化合物の塩を含む可溶性薬学的組成物 Pending JP2024525954A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163223711P 2021-07-20 2021-07-20
US63/223,711 2021-07-20
PCT/IB2022/056709 WO2023002407A2 (en) 2021-07-20 2022-07-20 Soluble pharmaceutical compositions comprising salts of disubstituted 1, 2, 4-triazine compound

Publications (2)

Publication Number Publication Date
JP2024525954A true JP2024525954A (ja) 2024-07-12
JP2024525954A5 JP2024525954A5 (https=) 2025-07-24

Family

ID=84978780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504002A Pending JP2024525954A (ja) 2021-07-20 2022-07-20 二置換１，２，４－トリアジン化合物の塩を含む可溶性薬学的組成物

Country Status (6)

Country Link
US (1) US20240366616A1 (https=)
EP (1) EP4373812A4 (https=)
JP (1) JP2024525954A (https=)
KR (1) KR20240052937A (https=)
CN (1) CN117957213A (https=)
WO (1) WO2023002407A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230069126A (ko) * 2020-09-15 2023-05-18 미쓰비시 타나베 파마 코퍼레이션 트리아진 화합물의 염, 그 결정형 및 제조 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212866D0 (en) * 2012-07-20 2012-09-05 Formac Pharmaceuticals Nv Dry granulates of mesoporous silica powders
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
KR20230069126A (ko) * 2020-09-15 2023-05-18 미쓰비시 타나베 파마 코퍼레이션 트리아진 화합물의 염, 그 결정형 및 제조 방법
JP2023546970A (ja) * 2020-10-26 2023-11-08 ミネラリス・セラピューティクス・インコーポレイテッド 高血圧のためのｃｙｐ１１ｂ２ベータヒドロキシラーゼ阻害剤

Also Published As

Publication number Publication date
CN117957213A (zh) 2024-04-30
EP4373812A4 (en) 2025-05-14
KR20240052937A (ko) 2024-04-23
EP4373812A2 (en) 2024-05-29
WO2023002407A3 (en) 2023-03-09
US20240366616A1 (en) 2024-11-07
WO2023002407A2 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
JP4757872B2 (ja) プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
WO2009101940A1 (ja) 溶出性の改善された錠剤
JP5622575B2 (ja) 固形バルサルタン組成物
EP3102187B1 (en) Stable pharmaceutical compositions containing sitagliptin in the form of immediate release tablets
JP2023184662A (ja) イストラデフィリン製剤
JP7821749B2 (ja) アカラブルチニブマレイン酸塩剤形
JP2020121950A (ja) 固形製剤
JP2024525954A (ja) 二置換１，２，４－トリアジン化合物の塩を含む可溶性薬学的組成物
WO2019219920A1 (en) Stable pharmaceutical compositions of dpp-iv inhibitors in combination with metformin in the form of immediate release tablets
WO2019073062A1 (en) TABLET CONTAINING VALSARTAN AND SACUBITRIL
JP2022012138A (ja) リナグリプチンと光安定化成分を含有する医薬製剤
WO2013091595A1 (en) Pharmaceutical formulation of prasugrel hydrobromide
TWI870615B (zh) 用於治療或預防高血壓和高血脂症之單一劑型的藥學組成物
JP7704830B2 (ja) シタグリプチン及びダパグリフロジンを含む複合製剤、及びその製造方法
HK40103672A (zh) 包括经二取代的1，2，4-三嗪化合物的盐的可溶性药物组合物
AU2020229265B2 (en) Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia
JP6765473B2 (ja) オルメサルタンのプロドラッグ製剤
EA033685B1 (ru) Фармацевтические лекарственные формы
EP2554164B1 (en) Pharmaceutical formulation based on ibuprofen and codeine having having improved stability
EP4633611A1 (en) Pharmaceutical composition of siponimod
JP2013203720A (ja) 錠剤の製造方法
WO2026050278A1 (en) Solid oral pharmaceutical formulations comprising a muscarinic receptor agonist
CA3237792A1 (en) Pharmaceutical composition having excellent dissolution properties
WO2025265110A1 (en) Oral pharmaceutical compositions comprising a naphthyridine compound
JP2026005776A (ja) 色素沈着症の予防又は治療用製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250715